1. In Vivo
  2. >>Deal-Making

The Top Five Pharma Stories Of 2023

 
• By Kevin Grogan

The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.

Number 5
• Source: Shutterstock

Breakthrough treatments are fortunately quite frequent but in 2023, the most excitement for an innovative product was reserved for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Casgevy (exagamglogene autotemcel), the first-ever CRISPR gene-edited medicine to get approval, firstly in the UK and then in the US, for sickle cell disease and transfusion-dependent beta thalassemia. (Also see "Vertex Achieves Gene-Editing Milestone With First Ever CRISPR Therapy Approval" - Scrip, 16 November, 2023.)

The thumbs-up stateside came on the same day in December that the US Food and Drug Administration approved bluebird...

More from Deal-Making

Deals Shaping The Industry, June 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By Ashley Yeo

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By Jo Shorthouse

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.